Skip to main content
Log in

Gastrointestinal uptake of FDG after N-butylscopolamine or omeprazole treatment in the rat

  • Short Communication
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective: Gastrointestinal (GI) uptake of 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) is frequently observed in whole-body positron emission tomography (PET) images. Such physiological uptake may interfere with accurate interpretation. The aim of the present study was to determine whether physiological gastrointestinal FDG uptake can be decreased by means of an antiperistaltic agent,N-butylscopolamine, or a gastric secretion inhibitor, omeprazole.Methods: Sprague-Dawley rats were divided into three groups: omeprazole-treated (n = 6),N-butylscopolamine-treated (n = 7), and control group (n = 6). The rats in the omeprazole-treated group were administered omeprazole (1.0 mg/kg) intravenously 45 minutes before FDG injection. The rats in theN-butylscopolamine-treated group were administered N-butylscopolamine ( 1.0 mg/kg) intramuscularly 10 minutes before FDG injection. Sixty minutes after FDG injection under overnight fasting state, the gastrointestinal tissues were excised and weighed to determine the radioactivity of18F using a gamma counter.Results: The mean values of FDG uptake in the esophagus, stomach, small intestine, cecum and colon of the N-butylscopolamine-treated group vs. the omeprazole-treated group were 148% vs. 162%, 109% vs. 113%, 113% vs. 88%, 102% vs. 85%, 105% vs. 70% of the control group, respectively. There were no statistical differences in FDG uptake rate in the esophagus, stomach, or cecum among the three groups. FDG uptake rates in the small intestine and colon of the omeprazole-treated group were significantly lower than those in the control group.Conclusion: Physiological FDG uptake in the GI tract was not decreased by the administration ofN-butylscopolamine. Omeprazole was effective in decreasing FDG uptake in the small intestine and colon. Omeprazole has a potential to decrease FDG uptake rate in a limited part of the GI tract.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants.Radiographics 1999; 19: 61–77.

    PubMed  CAS  Google Scholar 

  2. Gordon BA, Flanagan FL, Dehdashti F. Whole-body positron emission tomography: normal variations, pitfalls, and technical considerations.AJR 1997; 169: 1675–1680.

    PubMed  CAS  Google Scholar 

  3. Cook GJ, Maisey MN, Fogelman I. Normal variants, artifacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine.Eur J Nucl Med 1999; 26: 1363–1378.

    Article  PubMed  CAS  Google Scholar 

  4. Engel H, Steinert H, Buck A, Berthold T, Huch Boni RA, von Schulthess GK. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations.J Nucl Med 1996; 37: 441–446.

    PubMed  CAS  Google Scholar 

  5. Kim S, Chung JK, Kim BT, Kim SJ, Jeong JM, Lee DS. Relationship between gastrointestinal F-18-fluorodeoxy-glucose accumulation and gastrointestinal symptoms in whole-body PET.Clin Positron Imaging 1999; 2: 273–280.

    Article  PubMed  Google Scholar 

  6. Miraldi F, Vesselle H, Faulhaber PF, Adler LP, Leisure GP. Elimination of artifactual accumulation of FDG in PET imaging of colorectal cancer.Clin Nucl Med 1998; 23: 3–7.

    Article  PubMed  CAS  Google Scholar 

  7. Stahl A, Weber WA, Avril N, Schwaiger M. Effect ofN- butylscopolamine on intestinal uptake of fluorine-18-fluorodeoxyglucose in PET imaging of the abdomen.Nuklearmedizin 2000; 39: 241–245.

    PubMed  CAS  Google Scholar 

  8. Trenkner SW, Thompson WM. Imaging of gastrointestinal malignancies.Curr Opin Oncol 1992; 4: 736–740.

    Article  PubMed  CAS  Google Scholar 

  9. Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxy-glucose positron-emission tomography scanning: potential for error in interpretation.Semin Nucl Med 1996; XXVI: 308–314.

    Article  Google Scholar 

  10. Jadvar H, Tatlidil R, Garcia AA, Conti PS. Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography.Clin Radiol 2003; 58: 215–221.

    Article  PubMed  CAS  Google Scholar 

  11. Yee J, Hung RK, Akerkar GA, Wall SD. The usefulness of glucagon hydrochloride for colonic distention in CT colonography.AJR 1999; 173: 169–172.

    PubMed  CAS  Google Scholar 

  12. Goei R, Kessels AH, Nix M, Knipschild PG. Randomized clinical trial on the use of antispasmodic drugs in barium enema: impact on radiological practice.Eur J Radiol 2000; 36: 32–35.

    Article  PubMed  CAS  Google Scholar 

  13. Cittadini G, Sardanelli F, De Cicco E, Casiglia M, De Cata T, Parodi RC. Compared effect of a genetically engineered glucagon and hyoscine N-butylscopolamine on double-contrast barium meal study.Eur Radiol 1998; 8: 449–543.

    Article  PubMed  CAS  Google Scholar 

  14. Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole—a gastric proton pump inhibitor—on pentagastrin stimulated acid secretion in man.Gut 1983; 24: 270–276.

    Article  PubMed  CAS  Google Scholar 

  15. Yamamoto O, Okada Y, Okabe S. Effects of a proton pump inhibitor, omeprazole, on gastric secretion and gastric and duodenal ulcers or erosions in rats.Dig Dis Sci 1984; 29: 394–401.

    Article  PubMed  CAS  Google Scholar 

  16. Maton PN, Vakil NB, Levine JG, Hwang C, Skammer W, Lundborg P. Esomeprazole Study Investigators. Safety and efficacy of long term esomeprazole therapy in patients with healed erosive oesophagitis.Drug Saf 2001; 24: 625–635.

    Article  PubMed  CAS  Google Scholar 

  17. Richter JE, Kahrilas PJ, Johanson J, Maton P, Breiter JR, Hwang C. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.Am J Gastroenterol 2001; 96: 656–665.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Fumiyasu Yamamoto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yamamoto, F., Nakada, K., Zhao, S. et al. Gastrointestinal uptake of FDG after N-butylscopolamine or omeprazole treatment in the rat. Ann Nucl Med 18, 637–640 (2004). https://doi.org/10.1007/BF02984589

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02984589

Key words

Navigation